Clinical Trial Update: Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy [Phase 2]

View source ↗

Summary

Phase 2 open-label study of fostamatinib for IgA nephropathy has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Iga Nephropathy

Drugs mentioned

• Fostamatinib (fostamatinib)

Snippet

Sponsor: Rigel Pharmaceuticals | Conditions: IGA Nephropathy | Phase 2 | Status: WITHDRAWN